530207 — Brawn Biotech Income Statement
0.000.00%
Last trade - 00:00- IN₹51.01m
- IN₹37.04m
- IN₹134.65m
Annual income statement for Brawn Biotech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | PRESS |
| Standards: | IAS | IAS | — |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 222 | 165 | 135 |
| Cost of Revenue | |||
| Gross Profit | 30.5 | 21.3 | 15.3 |
| Selling / General / Administrative Expenses | |||
| Depreciation and Amortization | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 226 | 181 | 154 |
| Operating Profit | -4.13 | -16.2 | -18.9 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -4.12 | -15.4 | -18 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -8.68 | -12.5 | -18 |
| Net Income Before Extraordinary Items | |||
| Net Income | -8.68 | -12.5 | -18 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -8.68 | -12.5 | -18 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -2.89 | -4.14 | -5.87 |